In the current medical situation of sepsis, where mortality is unacceptably high in the absence of a reliable biomarker and specifically established therapy, our data imply a meaningful clue that a blood-circulating WARS1-targeting theranostic approach may help to improve the management of critically ill patients with sepsis based on a precision medicine strategy. The gene discussed is WARS1; the disease is Sepsis.